RemeGen Co., Ltd. (HKG:9995)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
88.35
-1.35 (-1.51%)
At close: Dec 5, 2025
406.01%
Market Cap 55.44B
Revenue (ttm) 2.43B
Net Income (ttm) -1.04B
Shares Out 555.94M
EPS (ttm) -1.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,150,000
Average Volume 4,624,065
Open 89.00
Previous Close 89.70
Day's Range 87.35 - 91.10
52-Week Range 11.52 - 126.60
Beta 0.86
RSI 51.13
Earnings Date Mar 26, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 2,999
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9995
Full Company Profile

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.